Dr. Paller’s team will further test a new Cyp26 inhibitor compound for comparison with the previously tested compounds, with and without retinoic acid, using 3D models of normal keratinocytes and RXLI/LI subgroups of ichthyosis keratinocytes. This includes growing patient keratinocytes, creating large numbers of normal and ichthyosis 3D cultures, and testing the effect of the compound/ retinoic acid for analysis of RNA and protein expression, as well as histological alteration. The Paller team will also have formal conferences with Dr. Diaz and Dermaxon LLC
|Effective start/end date||12/1/18 → 7/31/21|
- DermaXon LLC (2R44AR069416-02)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (2R44AR069416-02)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.